Fig. 3: Kaplan–Meier PFS and OS curves of dostarlimab plus chemotherapy and pembrolizumab plus chemotherapy. | Nature Communications

Fig. 3: Kaplan–Meier PFS and OS curves of dostarlimab plus chemotherapy and pembrolizumab plus chemotherapy.

From: Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Fig. 3

a PFS (data cut-off: August 4, 2022) and b OS (data cut-off: July 7, 2023) Note: + symbols represent individual censoring events. CI confidence interval, HR hazard ratio, NR not reached, OS overall survival, PFS progression-free survival.

Back to article page